ArticleArchives of medical science : AMS2012
Interleukin-17A and interleukin-23 in morphea.
Article in Archives of medical science : AMS, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- IL-17 Signaling Inhibitors in Localized Scleroderma: A Single-Center Case Series of Nine Patients.The Journal of dermatology · 2026Article
- Morphea Induced by Golimumab in a Patient With Ankylosing Spondylitis: A Case Report and Literature Review.Clinical case reports · 2026Article
- Unique and shared transcriptomic signatures underlying localized scleroderma pathogenesis identified using interpretable machine learning.JCI insight · 2025Article
- The role of selected cytokines from the interleukin 1 family in the pathophysiology of morphea.Archives of dermatological research · 2025Article
- What Is New in Morphea-Narrative Review on Molecular Aspects and New Targeted Therapies.Journal of clinical medicine · 2024Review
- Profiling of Toll-like Receptors and Related Signaling Mediators in the Pathogenesis of Morphea.Dermatology practical & conceptual · 2024Article
- Interferon-Gamma-Inducible Protein-10 (IP-10) and Tumor Necrosis Factor-α (TNF-α) as Serological Predictors of Active Disease Status in Localized Scleroderma.International journal of molecular sciences · 2024Article
- Investigative biological therapies for primary Sjögren's syndrome.Archives of medical science : AMS · 2024Article
- High dietary salt intake activates inflammatory cascades via Th17 immune cells: impact on health and diseases.Archives of medical science : AMS · 2022Article
- Morphea: progress to date and the road ahead.Annals of translational medicine · 2021Review
- Elevated Serum Interleukin-23 Levels in Patients with Oral and Cutaneous Lichen Planus.Mediators of inflammation · 2021Article
- Immunopathogenesis of Pediatric Localized Scleroderma.Frontiers in immunology · 2019Review
- Expression of selected genes of dendritic and Treg cells in blood and skin of morphea patients treated with UVA1 phototherapy.Archives of medical science : AMS · 2018Article
- Deletion of Mgr2p Affects the Gating Behavior of the TIM23 Complex.Frontiers in physiology · 2018Article
- Interleukin-17A Plays the Same Role on Mice Acute Lung Injury Respectively Induced by Lipopolysaccharide and Paraquat.Inflammation · 2017Article
- Morphea and Eosinophilic Fasciitis: An Update.American journal of clinical dermatology · 2017Review
- Effects of UVA1 Phototherapy on Expression of Human Endogenous Retroviral Sequence (HERV)-K10 gag in Morphea: A Preliminary Study.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- Significant reduction of peripheral blood interleukin-35 and CD4Central-European journal of immunology · 2017Article
- Evaluation of serum concentrations of the selected cytokines in patients with localized scleroderma.Postepy dermatologii i alergologii · 2016Article
- Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles.Seminars in arthritis and rheumatism · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMorphea is a disease included in the group of scleroderma type autoimmune diseases. Interleukin (IL)-17A may play a role at every stage of its pathogenesis. The study aimed at evaluation of IL-17A and IL-23 (as the main cytokine which is supposed to stimulate and maintain synthesis of IL-17) in pathogenesis of morphea. MATERIAL AND
methodsThe studies were performed on 41 blood samples from patients with morphea. Skin was sampled from 29 patients. The evaluation included: (1) expression of IL-17A and IL-23 genes in peripheral blood mononuclear cells (PBMC) using real-time polymerase chain reaction (PCR), (2) plasma concentrations of IL-17A and IL-23 using ELISA, (3) expression of IL-17A and IL-23 genes in skin using real-time PCR.
resultsThe results of gene expression are expressed as median number of copies per million copies of GAPDH. Higher expression of IL-17A has been demonstrated in PBMC of morphea vs. control group (2630 and 1906 respectively; p = 0.004), accompanied by absence of significant differences in its plasma concentration (10 pg/ml in both groups) and by lowered expression in affected skin (9119 and 19113 respectively; p = 0.036). The results failed to demonstrate elevated IL-23 plasma concentration in morphea vs. control group (5 pg/ml and 6 pg/ml respectively; p = 0.335) or its increased expression in the skin (292 vs. 427; p = 0.383), although we noted its increased expression in PBMC (4419 vs. 808; p < 0.001).
conclusionsBASED ON THE OBSERVED CORRELATIONS WE SUGGEST THAT: (1) IL-17A does not represent a factor which promotes tissue injury in morphea, (2) IL-23 may playa role in pathogenesis of morphea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.